CervoMed Inc. CRVO
CervoMed Inc. (Nasdaq: CRVO) is a CNS/neurology/psychiatry drug developer. Its lead program, neflamapimod, is in Phase 2 for Dementia with Lewy bodies (DLB) without AD co-pathology. Its next catalyst on record is neflamapimod (DLB): Planned Phase 3 trial initiation (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: neflamapimod (DLB) — Planned Phase 3 trial initiation (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| neflamapimod | Dementia with Lewy bodies (DLB) | small molecule | Phase 2 |
| neflamapimod | nonfluent variant primary progressive aphasia (nfvPPA) | small molecule | Phase 2 |
| neflamapimod | Rosah syndrome (RAS) | small molecule | Phase 2 |
| neflamapimod | Amyotrophic lateral sclerosis (ALS) | small molecule | Phase 2 |
Recent results and decisions
- Oct 29, 2026mixed RewinD-LB Phase 2b trial of neflamapimod in DLB did not confirm Phase 2a primary endpoint in full population but showed benefit in subgroups and biomarker effects.
Neflamapimod did not confirm the results of CervoMed's Phase 2a AscenD-LB clinical trial with respect to the primary outcome measure, change in Clinical Dementia Rating Sum of Boxes (CDR-SB), in the full intention-to-treat population.
Filing - Aug 4, 2026completed enrollment CervoMed recently completed enrollment in its Phase 2a trial of neflamapimod in nfvPPA.
CervoMed also recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nfvPPA
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.